The news story you are looking for has expired. A more recent related article is displayed below.

Sponsored Links

GenVec Receives Additional NIH Funding For HIV Vaccine

(Comment on this article at http://www.financialwire.net/2009/09/25/genvec-receives-additional-nih-funding-for-hiv-vaccine/)

September 25, 2009 (FinancialWire) -- GenVec, Inc. (NASDAQ: GNVC) said that the National Institutes of Health's National Institute of Allergy and Infectious Disease has executed its third option period under an existing five-year contract with GenVec valued at up to $52 million for the production of HIV vaccines.

The company said it will receive up to $2.3 million for the fourth year, which will support the generation of HIV vaccine candidates with GenVec's alternate adenovirus serotype technology.

Gaithersburg, Maryland-based GenVec is a biopharmaceutical company developing novel therapeutic drugs and vaccines. The company's lead product, TNFerade, is currently in a clinical study in locally advanced pancreatic cancer.

The drug is also being evaluated for its potential use in the treatment of several other cancers including esophageal cancer, rectal cancer, and head and neck cancer.

GenVec also uses its proprietary technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and HSV-2.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

http://www.financialwire.net

Copyright (C) 2009 Investrend. All rights reserved

News Provided by COMTEX


Related terms: cancer, clinical, contract, disease, drugs, health, hiv, maryland, nasdaq, respiratory, technology, vaccine, web

Related Articles

Conference Calls Today: 10 A.M. EDT - Zibb.com
Oct 19, 2009
...http://www.financialwire.net/news-alerts/), as well as free annual reports on those and thousands...other companies via the Free Annual Reports Service (http...level=279). FinancialWire(tm) is a fully independent...

Today on New Scientist: 20 October 2009
Oct 20, 2009
...any problems will strengthen the case for the project's cancellation First HIV vaccine trial success confirmed Further details on the first successful HIV vaccine confirm that it had an effect – although it was very modest Innovation: You...

Conference Calls Today: 11 A.M. EDT - Zibb.com
Oct 13, 2009
...http://www.financialwire.net/news-alerts/), as well as free annual reports on those and thousands...other companies via the Free Annual Reports Service (http...level=279). FinancialWire(tm) is a fully independent...

First HIV vaccine trial success confirmed
Oct 20, 2009
First HIV vaccine trial success confirmed Updated 18:12 20 October 2009 by Andy...For similar stories, visit the HIV and AIDS Topic Guide The first HIV vaccine to be called a success has stood up to scrutiny after further analysis...